Can you stop tucatinib/tucatinib once you take it?

When using Tucatinib (Tucatinib) to treat breast cancer , many patients are concerned about issues such as "whether it must be taken for a long time" and "whether the drug can be stopped after feeling good". Judging from overseas public information, the treatment concept of tucatinib is to "continue until disease progression or intolerable toxicity". In other words, tucatinib is not a drug that can be discontinued after a short "fixed course of treatment", but is a maintenance targeted therapy. Once started, if there are no serious adverse reactions and the efficacy continues, it is usually continued. If disease progression occurs during treatment (such as tumor enlargement, metastasis, or brain metastasis worsening) or severe intolerable side effects occur, the doctor may decide to stop or adjust the treatment.

In actual operation, if the patient achieves good curative effect, stable imaging, and improved quality of life during the medication period, he may consider continuing to take the medication and undergo regular evaluation. It also means interruptions can carry risks—such as tumor rebound and loss of control. Therefore, "stop taking your medication when you feel better" is not a recommended approach. A change in medication status may only be considered if the doctor assesses and confirms that the risk of discontinuation is controllable or the treatment plan is switched.

In addition, adverse reaction management must also be considered: Tucatinib may cause abnormal liver function, severe diarrhea, hand-foot syndrome, etc. If these toxicities occur, a protocol for dose reduction, temporary discontinuation, or permanent discontinuation may be followed. The decision to discontinue treatment should be made by the attending oncologist based on tumor response, patient status, concomitant treatment options, and tolerance.

In summary, once treatment with tucatinib is initiated, it is in principle recommended to continue its use until disease progression or unacceptable toxicity occurs. If patients consider discontinuing medication or modifying their treatment plan, they should communicate with their attending physician in detail and should not make decisions on their own.

Reference materials:https://www.tukysa.com/